

Docket No. 206704US0PCT

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE


IN RE APPLICATION OF: Hisaaki CHAKI, et al.

SERIAL NO: 09/830,559

FILED: May 7, 2001

RCE FILED: January 19, 2005

FOR: NOVEL COMPOUNDS AND PHARMACEUTICAL USE THEREOF



GAU: 1621

EXAMINER: P. G. O. SULLIVAN

INFORMATION DISCLOSURE STATEMENT UNDER 37 CFR 1.97

COMMISSIONER FOR PATENTS  
ALEXANDRIA, VIRGINIA 22313

SIR:

Applicant(s) wish to disclose the following information.

REFERENCES

- ☒ The applicant(s) wish to make of record the references cited in the attached European Search Report and listed on the attached form PTO-1449. Copies of the listed references are attached, where required, as are either statements of relevancy or any readily available English translations of pertinent portions of any non-English language references.
- ☐ A check or credit card payment form is attached in the amount required under 37 CFR §1.17(p).

RELATED CASES

- ☐ Attached is a list of applicant's pending application(s), published application(s) or issued patent(s) which may be related to the present application. In accordance with the waiver of 37 CFR 1.98 dated September 21, 2004, copies of the cited pending applications are not provided. Cited published and/or issued patents, if any, are listed on the attached PTO form 1449.
- ☐ A check or credit card payment form is attached in the amount required under 37 CFR §1.17(p).

CERTIFICATION


- ☒ Each item of information contained in this information disclosure statement was first cited in any communication from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of this statement.
- ☐ No item of information contained in this information disclosure statement was cited in a communication from a foreign patent office in a counterpart foreign application or, to the knowledge of the undersigned, having made reasonable inquiry, was known to any individual designated in 37 CFR §1.56(c) more than three months prior to the filing of this statement.

DEPOSIT ACCOUNT

- ☐ Please charge any additional fees for the papers being filed herewith and for which no check or credit card payment is enclosed herewith, or credit any overpayment to deposit account number 15-0030. A duplicate copy of this sheet is enclosed.

Respectfully submitted,

OBLON, SPIVAK, McCLELLAND,  
MAIER & NEUSTADT, P.C.  
Norman F. Oblon


  
Thomas M. Cunningham  
Registration No. 45,394

Customer Number

22850

Tel. (703) 413-3000  
Fax. (703) 413-2220  
(OSMMN 05/03)

James H. Knebel  
Registration No. 22,630

Form PTO 1449 (Modified)		U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE		ATTY DOCKET NO. <b>206704US0PCT</b>		SERIAL NO. <b>09/830,559</b>	
				APPLICANT <b>Hisaaki CHAKI, et al.</b>			
				FILING DATE <b>May 7, 2001</b> <b>RCE Filed: January 19, 2005</b>		GROUP <b>1621</b>	
				<b>U.S. PATENT DOCUMENTS</b>			
EXAMINER INITIAL	DOCUMENT NUMBER	DATE	NAME	CLASS	SUB CLASS	FILING DATE IF APPROPRIATE	
AA							
AB							
AC							
AD							
<b>FOREIGN PATENT DOCUMENTS</b>							
	DOCUMENT NUMBER	DATE	COUNTRY		TRANSLATION YES NO		
AE	EP 0 856 582	08/05/1998	EUROPE				
AF							
AG							
AH							
AI							
AJ							
AK							
AL							
<b>OTHER REFERENCES (Including Author, Title, Date, Pertinent Pages, etc.)</b>							
AM	Andrea FANJUI, et al., "A NEW CLASS OF RETINOIDS WITH SELECTIVE INHIBITION OF AP-1 INHIBITS PROLIFERATION," LETTER TO NATURE, XP-000579772, Vol. 372, No. 6501, November 3, 1994, Pages 107-111						
AN	Robert W. SULLIVAN, et al., "2-CHLORO-4-(TRIFLUOROMETHYL)PYRIMIDINE-5-N-(3',5'-BIS(TRIFLUOROMETHYL)PHENYL)-CARBOXAMIDE: A POTENT INHIBITOR OF NF-Kb- AND AP-1-MEDIATED GENE EXPRESSION IDENTIFIED USING SOLUTION-PHASE COMBINATORIAL CHEMISTRY," JOURNAL OF MEDICINAL CHEMISTRY, AMERICAN CHEMICAL SOCIETY, XP-002328712, Vol. 41, No. 4, January 24, 1998, Pages 413-419						
AO	M. E. GOLDMAN, et al., "SP100030 IS A NOVEL T-CELL-SPECIFIC TRANSCRIPTION FACTOR INHIBITOR THAT POSSESSES IMMUNOSUPPRESSIVE ACTIVITY IN VIVO," TRANSPLANTATION PROCEEDINGS, XP-001095817, Vol. 28, No. 6, December 1996, Pages 3106-3109						
AP	Masaki GOTO, et al., "K1115 A, A NEW ANTHRAQUINONE DERIVATIVE THAT INHIBITS THE BINDING OF ACTIVATOR PROTEIN-1 (AP-1) TO ITS RECOGNITION SITES," THE JOURNAL OF ANTIBIOTICS, XP-008066756, Vol. 51, No. 6, June 1998, Pages 539-544						
AQ	Keiichi TSUCHIDA, et al., "DESIGN, SYNTHESIS AND BIOLOGICAL EVALUATION OF NEW CYCLIC DISULFIDE DECAPEPTIDES THAT INHIBIT THE BINDING OF AP-1 TO DNA," JOURNAL OF MEDICINAL CHEMISTRY, XP-002390592, Vol. 47, No. 17, August 12, 2004, Pages 4239-4246						
AR							
AS							
AT						<input type="checkbox"/> Additional References sheet(s) attached	
Examiner					Date Considered		
*Examiner: Initial if reference is considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.							